Direct-to-Patient (DTP) Logistics in Clinical Trials

Introduction: The Rise of DTP Logistics

Direct-to-Patient (DTP) logistics—delivering investigational medicinal products (IMPs) directly to patients’ homes—has emerged as a cornerstone of decentralized clinical trials (DCTs). For US sponsors, the FDA has increasingly focused on DTP oversight due to risks in chain of custody, temperature control, and accountability. While DTP models improve patient convenience and recruitment, they also introduce compliance challenges, requiring meticulous planning, vendor oversight, and regulatory alignment.

According to WHO’s International Clinical Trials Registry Platform, over 25% of ongoing global trials now use some form of direct-to-patient supply. However, inspection findings highlight recurring deficiencies in documentation, courier oversight, and training—areas sponsors must prioritize to achieve inspection readiness.

Regulatory Expectations for DTP Oversight

The FDA, EMA, and ICH provide clear expectations for DTP logistics:

• FDA 21 CFR Part 312.57: Requires sponsors to maintain records of shipment and disposition of investigational drugs, including DTP deliveries.
• FDA 21 CFR Part 211: Requires drug storage and distribution under conditions that preserve quality.
• ICH E6(R3): Assigns responsibility for IMP accountability and documentation to both sponsors and investigators, even in home delivery models.
• EMA GDP: Requires couriers and depots supporting DTP supply to be qualified and to maintain validated cold chain processes.

Regulators also expect sponsors to integrate privacy and consent safeguards, ensuring patient data protection in home delivery records.

Audit Findings in DTP Supply Chains

Common deficiencies observed in FDA and sponsor audits include:

Example: In a 2020 FDA inspection of a decentralized oncology trial, the sponsor was cited for inadequate accountability of home-delivered IMPs. Couriers lacked GDP training, and custody documentation was incomplete.

Root Causes of DTP Oversight Failures

Root causes of deficiencies in DTP logistics typically include:

• Absence of SOPs for DTP shipment, receipt, and reconciliation.
• Untrained courier staff handling temperature-sensitive products.
• Lack of contractual controls preventing unauthorized subcontracting.
• Failure to integrate DTP documentation into the Trial Master File (TMF).

Case Example: In a rare disease trial, IMPs were delivered without chain-of-custody documentation. Investigation revealed that couriers used subcontractors without sponsor authorization, resulting in FDA findings.

Corrective and Preventive Actions (CAPA) for DTP Logistics

Sponsors must integrate CAPA into DTP oversight to prevent recurring issues:

1. Immediate Correction: Quarantine affected IMPs, notify patients and investigators, and reconcile custody logs.
2. Root Cause Analysis: Identify whether failures stemmed from SOP gaps, vendor oversight deficiencies, or training issues.
3. Corrective Actions: Revise SOPs to include DTP workflows, requalify couriers, and retrain staff.
4. Preventive Actions: Conduct periodic courier audits, implement GPS and real-time monitoring, and require sponsor approval for subcontractors.

Example: A US sponsor implemented digital dashboards linking courier data with IRT systems. This improved accountability, reduced missing shipment logs by 90%, and satisfied FDA inspection requirements.

Best Practices in Direct-to-Patient Oversight

Best practices for US sponsors to strengthen DTP compliance include:

• Develop comprehensive SOPs covering all aspects of home delivery.
• Qualify and requalify couriers through GDP/GCP-focused audits.
• Use validated temperature-controlled packaging with electronic monitoring.
• Integrate DTP delivery documentation into TMF systems for inspection readiness.
• Train site staff and couriers on privacy, consent, and accountability requirements.

KPIs for DTP oversight:

Case Studies of DTP Deficiencies

Case 1: FDA cited a sponsor for missing DTP accountability logs in a rare disease trial, requiring CAPA.
Case 2: EMA inspection identified courier subcontracting without approval in an EU decentralized study.
Case 3: WHO review observed confidentiality breaches in DTP shipments in a global vaccine trial, recommending enhanced privacy controls.

Conclusion: Making DTP Oversight a Compliance Priority

Direct-to-Patient logistics is a growing model in decentralized trials but introduces high compliance risks. For US sponsors, FDA requires complete documentation, qualified couriers, validated packaging, and privacy safeguards. By embedding CAPA, digitizing oversight, and adopting best practices, sponsors can ensure inspection readiness while supporting patient-centric trial models.

Sponsors who elevate DTP oversight from a logistical task to a compliance-critical function achieve both operational flexibility and regulatory trust, ensuring successful decentralized trials.